JP2018518522A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518522A5
JP2018518522A5 JP2017567214A JP2017567214A JP2018518522A5 JP 2018518522 A5 JP2018518522 A5 JP 2018518522A5 JP 2017567214 A JP2017567214 A JP 2017567214A JP 2017567214 A JP2017567214 A JP 2017567214A JP 2018518522 A5 JP2018518522 A5 JP 2018518522A5
Authority
JP
Japan
Prior art keywords
inhibitor
amino
methyl
group
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039022 external-priority patent/WO2016210134A1/en
Publication of JP2018518522A publication Critical patent/JP2018518522A/ja
Publication of JP2018518522A5 publication Critical patent/JP2018518522A5/ja
Pending legal-status Critical Current

Links

JP2017567214A 2015-06-23 2016-06-23 癌を治療するための組成物及び方法 Pending JP2018518522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183517P 2015-06-23 2015-06-23
US62/183,517 2015-06-23
PCT/US2016/039022 WO2016210134A1 (en) 2015-06-23 2016-06-23 Compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2018518522A JP2018518522A (ja) 2018-07-12
JP2018518522A5 true JP2018518522A5 (enExample) 2019-07-25

Family

ID=57586472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567214A Pending JP2018518522A (ja) 2015-06-23 2016-06-23 癌を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US10744141B2 (enExample)
EP (1) EP3313819A1 (enExample)
JP (1) JP2018518522A (enExample)
CN (1) CN108779073A (enExample)
AU (1) AU2016281646A1 (enExample)
CA (1) CA2990835A1 (enExample)
IL (1) IL256523A (enExample)
WO (1) WO2016210134A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US12398103B2 (en) * 2020-03-20 2025-08-26 Atux Iskay Llc 3-diarylmethylenes and uses thereof
JP2023519931A (ja) * 2020-04-01 2023-05-15 エンジン バイオサイエンシズ プライベート リミテッド 癌を治療するための方法及び組成物
WO2022094615A1 (en) * 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
CN114617969B (zh) * 2020-12-14 2023-08-25 上海市肿瘤研究所 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
MX2023009248A (es) * 2021-02-08 2023-08-16 Rappta Therapeutics Oy Moduladores ciclicos sustituidos de proteina fosfatasa 2a (pp2a) y metodos que utilizan los mismos.
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
CN118119607A (zh) 2021-08-18 2024-05-31 阿图什伊斯卡伊有限责任公司 作为抗癌、抗炎、抗纤维和神经保护剂的2-二芳基甲基-4-氨基四氢吡喃衍生物及相关化合物
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN114984221A (zh) * 2022-05-25 2022-09-02 浙江大学 Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用
CN116421726A (zh) * 2023-04-14 2023-07-14 中国海洋大学 一种基于分子预测的靶向plk1纳米药物的开发方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20090020197A1 (en) * 2007-07-16 2009-01-22 Key Safety Systems, Inc. Gas generating compositions and airbag inflators
US20110033461A1 (en) 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
WO2009117769A1 (en) * 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition of c-kit cancers
JP2012523458A (ja) * 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
KR20140070550A (ko) * 2011-08-16 2014-06-10 마운트 시나이 스쿨 오브 메디슨 항암제로서의 삼환식 화합물
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
EP2971092B1 (en) 2013-03-15 2020-04-22 Life Technologies Corporation Prognostic assay for squamous cell lung carcinoma
CN106458936A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 作为抗癌药的三环‑2‑氨基环烷醇衍生的磺酰胺
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides

Similar Documents

Publication Publication Date Title
JP2018518522A5 (enExample)
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
KR102396930B1 (ko) 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
RU2018123779A (ru) Новые соединения
JP2024502886A (ja) がんを処置及び/又は予防するためのsos1阻害薬の医薬組合せ
AU2017376629B2 (en) Benzimidazole compounds as c-Kit inhibitors
JP6549311B2 (ja) インドール誘導体、その調製方法および医薬におけるその使用
JP2020503299A5 (enExample)
PE20212069A1 (es) Compuesto inhibidor de jak y uso del mismo
Frey et al. 7-Aminopyrazolo [1, 5-a] pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors
KR20180134983A (ko) Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
JP2008514643A5 (enExample)
JP2011507854A5 (enExample)
JP2009523812A5 (enExample)
PE20090596A1 (es) Imidazoles biciclicos fusionados
JP2016504290A5 (enExample)
JP2008525498A (ja) 酵素モジュレータ及び治療
JP2020504747A5 (enExample)
ME02203B (me) Hinolin i hinoksalin derivati kao inhibitori kinaza
JP2006522812A5 (enExample)
JP2007519694A5 (enExample)
WO2013118071A1 (en) BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
JP2011510995A5 (enExample)
RU2404163C2 (ru) Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
JP2018501209A5 (enExample)